Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
US Market
Holding KYTX?
Track your performance easily

Kyverna Therapeutics, Inc. (KYTX) Income Statement

617 Followers

Kyverna Therapeutics, Inc. Income Statement

Last quarter (Q2 2024), Kyverna Therapeutics, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Kyverna Therapeutics, Inc.'s net income was $-28.80M. See Kyverna Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21
Total Revenue
--$ 7.03M-
Cost of Revenue
----
Gross Profit
--$ 7.03M-
Operating Expense
$ 54.81M$ 62.41M$ 36.41M-
Operating Income
$ -54.81M$ -62.41M$ -29.38M-
Net Non Operating Interest Income Expense
$ 5.40M$ 2.10M$ 500.00K-
Other Income Expense
$ 55.00K$ -55.00K$ 9.00K-
Pretax Income
$ -49.47M$ -60.37M$ -28.89M-
Tax Provision
----
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
$ -49.47M$ -60.37M$ -28.89M-
Basic EPS
$ -26.61$ -89.61$ -63.43-
Diluted EPS
$ -26.61$ -89.61$ -63.43-
Basic Average Shares
$ 43.92M$ 673.62K$ 455.48K-
Diluted Average Shares
$ 43.92M$ 673.62K$ 455.48K-
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
$ 54.81M$ 62.41M$ 36.41M$ 32.00M
Net Income From Continuing And Discontinued Operation
$ -49.47M$ -60.37M$ -28.89M-
Normalized Income
$ -28.51M---
Interest Expense
----
EBIT
$ -28.76M---
EBITDA
$ -27.95M---
Currency in USD

Kyverna Therapeutics, Inc. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis